HC Wainwright & Co. Maintains Buy on Nemaura Medical, Lowers Price Target to $2.5
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Yi Chen maintains a 'Buy' rating on Nemaura Medical (NASDAQ:NMRD) but lowers the price target from $7 to $2.5.
August 21, 2023 | 10:33 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Despite the lowered price target from $7 to $2.5, HC Wainwright & Co. maintains a 'Buy' rating on Nemaura Medical.
The lowered price target could potentially indicate a bearish outlook for the stock. However, the maintained 'Buy' rating suggests that the analyst still sees potential upside, which could balance out the negative impact of the lowered price target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100